Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVIRN3)

Drug Name
N-DESMETHYLCLOZAPINE Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizoaffective disorder 6A21 Phase 2 [1]
Schizophrenia 6A20 Phase 2 [1]
Cross-matching ID
PubChem CID
135409468
ChEBI ID
CHEBI:64050
CAS Number
CAS 6104-71-8
TTD Drug ID
DMVIRN3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [5]
Fesoterodine fumarate DM13495 Overactive bladder GC50.0 Approved [6]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [7]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [8]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [9]
Oxyphenonium DMMQHOZ Visceral spasms MD81.4 Approved [10]
Benztropine DMGZOVN Parkinson disease 8A00.0 Approved [11]
Glycopyrrolate DM2M3ZA Anaesthesia 9A78.6 Approved [12]
Pirenzepine DMP6M1N Peptic ulcer DA61 Approved [13]
Cycrimine DM8C43Q Parkinson disease 8A00.0 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2A (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [15]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [16]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [17]
Haloperidol DM96SE0 Delirium Approved [17]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [18]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [19]
Olanzapine DMPFN6Y Bipolar depression Approved [20]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [21]
Arsenic DMTL2Y1 N. A. N. A. Approved [22]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [24]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [25]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [26]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [27]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [28]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [29]
Ethacrynic acid DM60QMR Edema MG29 Approved [30]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [31]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [32]
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [34]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [35]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [36]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [37]
Capsaicin DMGMF6V Back pain ME84.Z Approved [38]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [39]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [40]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [39]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [35]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [34]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [41]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [39]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [36]
Capsaicin DMGMF6V Back pain ME84.Z Approved [38]
Zafirlukast DMHNQOG Asthma CA23 Approved [42]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [39]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [43]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [36]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [44]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [45]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [44]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [45]
Sulfinpyrazone DMEV954 Gout FA25 Approved [46]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [44]
Zafirlukast DMHNQOG Asthma CA23 Approved [44]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [44]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [47]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2J2 (CYP2J2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [49]
Quercetin DM3NC4M Obesity 5B81 Approved [50]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [51]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [52]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [53]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [49]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [54]
Amlodipine DMBDAZV Angina pectoris BA40 Approved [49]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Gemfibrozil DMD8Q3J Hyperlipidaemia 5C80 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [57]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [57]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [57]
Capsaicin DMGMF6V Back pain ME84.Z Approved [38]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [58]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [40]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [59]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [60]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [61]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [62]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [34]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [63]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [36]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [39]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [39]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [64]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [65]
Capsaicin DMGMF6V Back pain ME84.Z Approved [66]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [62]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [34]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [65]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [65]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [68]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [69]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [54]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [18]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [25]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [72]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [73]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [74]
Estrone DM5T6US Acne vulgaris ED80 Approved [75]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [76]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [77]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [78]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [79]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [81]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [82]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [83]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [84]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [85]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [86]
Capsaicin DMGMF6V Back pain ME84.Z Approved [38]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [39]
Quinidine DMLPICK N. A. N. A. Approved [87]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [88]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Modulator [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Gene/Protein Processing [3]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Biotransformations [4]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Biotransformations [4]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Biotransformations [4]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Biotransformations [4]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Biotransformations [4]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Biotransformations [4]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Biotransformations [4]
Cytochrome P450 2J2 (CYP2J2) OTJBTEH8 CP2J2_HUMAN Biotransformations [4]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 333).
2 N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95.
3 Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):297-302. doi: 10.1016/j.pnpbp.2003.10.008.
4 Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008 Dec;36(12):2547-55. doi: 10.1124/dmd.108.023671. Epub 2008 Sep 22.
5 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
8 Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
9 The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
10 Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
11 Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
12 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
13 Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
14 Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
15 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
16 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
17 Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
18 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
19 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
20 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
21 Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
22 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
23 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
24 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
25 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
26 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
27 Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
28 Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
29 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
30 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
31 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
32 The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
33 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
34 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
35 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
36 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
37 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
38 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
39 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
40 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
41 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
42 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
43 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
44 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
45 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
46 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
47 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
48 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
49 Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
50 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
51 In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica. 2003 Jun;33(6):615-23.
52 Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006 Dec;319(3):1162-71.
53 Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. Arch Toxicol. 2021 Mar;95(3):907-922. doi: 10.1007/s00204-020-02953-6. Epub 2020 Dec 2.
54 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
55 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
56 Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
57 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
58 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
59 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
60 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
61 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
62 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
63 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
64 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
65 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
66 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
67 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
68 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
69 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
70 Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
71 Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
72 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
73 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
74 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
75 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
76 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
77 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
78 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
79 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
80 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
81 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
82 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
83 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
84 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
85 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
86 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
87 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
88 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.